- Home
- APRE vs INBS Comparison
APRE vs INBS Comparison
Compare APRE & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- INBS
- Stock Information
- Founded
- APRE 2006
- INBS 2016
- Country
- APRE United States
- INBS United States
- Employees
- APRE N/A
- INBS N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- INBS Medical Specialities
- Sector
- APRE Health Care
- INBS Health Care
- Exchange
- APRE Nasdaq
- INBS Nasdaq
- Market Cap
- APRE 8.3M
- INBS 9.6M
- IPO Year
- APRE 2019
- INBS N/A
- Fundamental
- Price
- APRE $1.39
- INBS $1.02
- Analyst Decision
- APRE Strong Buy
- INBS
- Analyst Count
- APRE 1
- INBS 0
- Target Price
- APRE $20.00
- INBS N/A
- AVG Volume (30 Days)
- APRE 141.8K
- INBS 395.6K
- Earning Date
- APRE 11-07-2025
- INBS 11-07-2025
- Dividend Yield
- APRE N/A
- INBS N/A
- EPS Growth
- APRE N/A
- INBS N/A
- EPS
- APRE N/A
- INBS N/A
- Revenue
- APRE $841,012.00
- INBS $3,052,532.00
- Revenue This Year
- APRE N/A
- INBS $778.48
- Revenue Next Year
- APRE N/A
- INBS N/A
- P/E Ratio
- APRE N/A
- INBS N/A
- Revenue Growth
- APRE N/A
- INBS N/A
- 52 Week Low
- APRE $1.31
- INBS $0.91
- 52 Week High
- APRE $5.00
- INBS $2.75
- Technical
- Relative Strength Index (RSI)
- APRE 42.40
- INBS 44.95
- Support Level
- APRE $1.31
- INBS $0.91
- Resistance Level
- APRE $1.46
- INBS $1.06
- Average True Range (ATR)
- APRE 0.09
- INBS 0.07
- MACD
- APRE -0.01
- INBS 0.01
- Stochastic Oscillator
- APRE 22.11
- INBS 52.96
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.